TRAVERE THERAPEUTICS

Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

09 Feb 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jan 2022 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2022 Outlook

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

04 Jan 2022 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

15 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Dec 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

11 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021

02 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress

28 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2021 Financial Results

14 Oct 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Oct 2021 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Transition of Chief Medical Officer

12 Oct 2021 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand

15 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors

14 Sep 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Sep 2021 17:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis

07 Sep 2021 08:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

16 Aug 2021 07:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2021 Financial Results

29 Jul 2021 16:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2021 Financial Results

22 Jul 2021 16:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Jul 2021 16:30:00 By Nasdaq GlobeNewswire